Biocept Inc (BIOC) drops 22% hurting investors
Biocept Inc (BIOC) currently trades at $0.46 and has fallen by 22.88% today. BIOC went down $0.14 from the previous closing price of $0.60. The high forecast for Biocept Inc is $1.00 and the low is $0.20. The company’s market cap is $50.57 million with a 52 week high of $2.11 and a 52 week low of $0.21. BIOC has changed in price by -0.56 per share in the last 12 months.
Biocept Inc has a weak EPS of -1.22. This means the company lost $-1.22 per share after paying dividends, this can indicate that the stock is a risky investment. EPS is calculated as a company’s profit divided by the outstanding shares of its common stock. The resulting number serves as an indicator of a company’s profitability. It is common for a company to report EPS that is adjusted for extraordinary items and potential share dilution. Based on this information, investorsQ rates this stock 3 out of 10. We give it this rating based on current information written in this article.
About Biocept Inc:
Biocept, Inc. is a commercial-stage cancer diagnostics company. The Company focuses on developing and commercialization proprietary circulating tumor cell and circulating tumor DNA tests. Biocept serves patients and customers in the State of California.